A METHOD FOR THE REDUCTION OF OXYGENATED COMPOUNDS OF RHENIUM OR TECHNETIUM

Abstract: A method for the reduction of oxygenated compounds of rhenium or technetium with a reducing agent, wherein the reduction reaction is carried out in the presence of a macromolecular compound selected from the group consisting of cylic oligosaccharides, crown ethers and cryptands, wherein said macromolecular compound is effective to displace the equilibrium of the reduction reaction toward the formation of the reduced species of said oxygenated compound. The reduction reaction is preferably carried out in the presence of a ligand which can form a complex with rhenium or technetium to provide Tc or Re radiopharmaceuticals.

Description: A method for the reduction of oxygenated compounds of rhenium or technetium The present invention relates in general to a method for the reduction of oxygenated compounds of rhenium and technetium and in particular to reduction of perrhenate or pertechnetate ions . More particularly, the invention relates to reactions for the reduction of the said oxygenated compounds which are carried out in the course of the preparation of complexes of the radionuclides l 6 Re, |, 'Re and Wm Tc; in these reactions, the radionuclide perrhenate or pertechnetate ion is reduced in the presence of a reducing agent and a ligand which can form a complex with the radionuclide in its reduced oxidation state. It is known that the radionuclides ""'Re, l Re and w " ' Tc have nuclear properties which make their coordination compounds suitable for application in nuclear medicine as therapeutic and diagnostic agents. Although the similarity between the chemical properties of technetium and rhenium lead one to think that a method of synthesising W "" c radiopharmaceuticals might simply be transferred to the preparation of similar tracers of "" " Re and lx, Re, there are, however, fundamental differences between the properties of the two elements such as to make the possible use of rhenium compounds in nuclear medicine subject to certain conditions . In fact, since the metals technetium and rhenium in their highest oxidation states and, in particular, the tetraoxygenated anions [M0 4 ] ~ (M = Re, Tc) are the principal starting materials for the synthesis of radiopharmaceuticals of rhenium and technetium, the result is that the reduction potentials of these species play a very important role determining the course of the synthesis reactions. In particular, it is known that the reduction potential of the pertechnetate anion is considerably greater than that of the perrhenate anion. This indicates that, once a given synthesis has been determined, it must be much easier to prepare a technetium complex than the analogous rhenium complex. In general, it is possible for a given synthesis adopted to obtain a radiopharmaceutical from w '"Tc to give a very much lower reaction yield in the case of rhenium. This conclusion is even more significant when one considers that, in the therapeutic application of rnenium compounds, the final product must have a very high radiochemical purity to reduce radiological risks. The considerations set out above show that, to produce radiopharmaceutical preparations involving metal complexes of the radionuclides 1 ή Re and l s Re, it is necessary to provide a method of synthesis which is very efficient at reducing the perrhenate ion. US 4455291 discloses that various "accelerators" are useful to facilitate the preparation of cationic W Tc complexes. Accelerators include oxalic acid, tartaπc acid and ascorbic acid. US 4871836 discloses that lή Re/ l 8 Re kits can usefully contain an "accelerator (catalyst)", preferably citric acid, tartaric acid and malonic acid. Example 9 discloses a freeze-dried kit for the preparation of lxή Re complexes from perrhenate which includes both citric acid and cyclodextr the formulation. The cyclodextnn is described as a solubiliser. US 5026913 discloses that cyclodextrins can be used as solubilisers in kits for the preparation of Wm Tc radiopharmaceuticals . US 5300280 discloses a method of stabilising radiopharmaceutical kits using cyclic oligosaccharides (cyclodextrins) to inhibit oxidation and/or volatilisation of the kit components. l,6 Re, l,, Re and Wm τc are specifically claimed . DD 265628 discloses a method for the production of in vivo stable Wn' Tc pertechnetate crown ether coordination compounds , wherein crown ethers are reacted stoichiometrically with Sn "" cations and sodium " ' Tc- pertechnetate is added in a stoichiometric amount. A specific object of the present invention is to provide a more efficient method for the reduction of oxygenated compounds of rhenium and, in particular, of the perrhenate ion . Another object is to provide a general method of synthesis of radiopharmaceuticals of rhenium, applicable to the preparation of different classes of compounds under sterile and apyrogenic conditions . With reference to technetium, although its reduction potential is more favourable than that of rhenium, its reduction in the presence of specific ligands to form a complex may be very difficult depending upon the specific ligand used. For this reason, there is also a need to provide a more efficient method of reducing technetium which facilitates the formation of the desired complex without the need to adopt particularly drastic reduction conditions and a further object of the present invention results from this need. In view of the aforesaid objects, a subject of the present invention is a method for the reduction of oxygenated compounds of rhenium or technetium, carried out in the presence of a reducing agent, wherein the reduction is carried out in the presence of a macromolecular compound selected from the group consisting of cyclic oligosaccharides, crown ethers and cryptands, said macromolecular compound being effective to displace the equilibrium of the reduction reaction toward the formation of the reduced species of the rhenium or technetium. The reduction process to which the invention relates, makes use of the supramolecular interactions known as host-guest interactions. It is known that a host-guest interaction consists of the formation of a supramolecular aggregate of two species, of which the first (host) is characterised by the presence of a molecular cavity sufficiently large to house the second (guest) which is of smaller dimensions. The forces which cause the smaller molecule to be trapped generally belong to the category of weak interactions (van der Waals interactions, hydrogen bonding, hydrophilic and hydrophobic interactions, London forces) and thus do not alter the chemical nature of the species enclosed in the cavity. The host molecules used in the process of the invention include cyclic oligosaccharides such as, in particular, modified or unmodified cyclodextrins, crown ethers and cryptands . The modified or unmodified cyclodextrins usable in the invention include -cyclodextrins , / 3-cyclodextrin, 7- cyclodextrin and their mixtures. γ-cyclodextrins are particularly preferred. By way of example, hydroxypropyl- -cyclodextrin and hydroxyethyl-oc- cyclodextrin may be used as the a- cyclodextrin; hydroxypropyl- / 3-cyclodextrin, carboxymethyl- jS-cyclodextrin, dihydroxypropyl-β-cyclodextrin, hydroxyethyl-ø-cyclodextrin , 2 , 6-di-o-methy 1-0-cyclodextrin and sulphated 0-cyclodextrin may be used as the β- cyclodextrin; hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-γ-cyclodextrin, hydroxypropyl-γ- cyclodextrin and sulphated 7-cyclodextrin may be used as the γ-cyclodextrin . A full review of the cyclodextrins usable as host molecules in supramolecular structures is provided in the article by G. enz in Angew, Chem. Int. ed.engl., 1994, 33, 803-822 incorporated herein by reference. As crown ethers there may be used crown ethers available commercially and their derivates such as, for example, the compounds given in the Fluka 1995/96 catalogue, p 419, among which in particular are the 12-crown-4, 15-crown-5 and 18-crown-6 ethers and their derivatives. It is understood that, in embodiments of the invention which relate to the production of radiopharmeceutical complexes, the host molecules used must be pharmaceutically acceptable . The quantity of host molecule used in the process of the invention is not particularly critical and is generally in the stoichiometric ratio or in excess with respect to the rhenium or technetium. The reducing agents which may be used within the scope of the invention are any reducing agents able to reduce the compound or anion of rhenium or technetium. The preferred reducing agents for the perrhenate and pertechnetate anions comprise Sn 1+ , Fe ,+ and Cu' + , of which the stannous ion, which is widely used in radiopharmaceutical preparations, is preferred. These ions may be introduced into the reaction medium in the form of halides, particularly the chlorides, or in the form of inorganic salts such as phosphonates and organic salts, particularly salts of polycarboxylic acids, such as tartrates, citrates, oxalates, gluconates and glucoheptanates . Other reducing agents incluαe phosphmes, such as triphenylphosphine, tris (2- sulphonatophenyl )phosphme, tris ( cyanoethyl )phosphme, sodium borohydride, alkali metal thiosulphates , dithionites and dithionates . According to a preferred embodiment, the reduction reaction is carried out m the presence of a polycarboxylic acid or metal salt thereof (preferably an alkali metal salt), such as oxalate, citrate, ascorbate, malonate or tartrate, which acts as a secondary reducing agent. Oxalate is highly preferred . The ligands used in the invention include ligands used in radiopharmaceutical kits such as, for example, phosphmes, phosphonates, arsmes, thiols, thioethers, isonitriles, amines, cyclic amines, polyammes, dithiocarbamates , dithiocarboxylates , Schiff bases, diam odithiols , bis ( ammo ) thiols , oximes, sugars, borates, ammo acids, polyammo acids, ligands including combinations of these groups and peptide ligands. In general the ligand may comprise any molecule that has atoms which are able to coordinate w th the central rhenium or technetium metal on to form a stable complex or a complex which can give rise to substitution reactions with other ligands. It is also possible to use the methods described in the invention to produce radiopharmaceuticals of " 6 Re and |,x Re, characterised by the presence, in the structure of the complex, of the terminal rhenium-nitride triple bond, Re≡N, through the use of suitable donor molecules of nitride groups N ,_ such as hydrazine, hydrazine derivatives, derivatives of dithiocarbazic acid, sodium azide and, in general, molecules containing the functional >N-N< group. One embodiment of the invention includes the choice of coordinating ligands which satisfy one or both of the following requisites: a) the ligand used promotes the stabilisation of the reduced species which forms as a result of the reduction of the perrhenate or pertechnetate ion; and b) forms a complex with the reduced species which can give rise to a substitution reaction with other ligands. The requisite b) takes account of the fact that the coordination compound produced by the method given by the above process, and containing the metal ion in a lower oxidation state, in turn constitutes a pre-reduced intermediate through which it is possible to obtain the final complexes by means of simple substitution reactions. In this embodiment, it is preferable to use ligands, such as oxalate and citrate, in the reduction reaction which are able to promote the electroreduction of the [Re0 4 ] " anion" and which do not give rise to stable complexes with rhenium, particularly in oxidation states less than +7. In this embodiment, the reaction is carried out in the presence of a first ligand which satisfies requirements a) and b), particularly oxalate and citrate, and a second ligand suitable for the preparation of a specific radiopharmaceutical and capable of replacing completely the first ligand which coordinates weakly with the metal centre (i.e. ligand displacement or transchelation) . Examples of phosphme ligands for use m radiopharmaceutical kits include tris ( 3-ethoxypropyl )phos- phine, tπmethylphosphine, tnethylphosphme, tris (3- methoxy-3-methylbutyl ) phosphme, tris ( 3-methoxy- propyl ) phosphme, tris [ 2-[ 2 ( 1 , 3-dιoxanyl ) ] ] ethylphosphme, methylb s ( 3-methoxypropyl )phosphme, tris ( 4-metnoxy- butyl )phosphιne, dimethyl ( 3-methoxypropyl ) phosphme, methylbis [ 2-[ 2- ( 1 , 3-dιoxanyl )]] ethylphosphme and bιs(l,2- dimethylphosphme ) ethane . As peptide ligands there may, for example, be used the peptides modified with a phosphme group described m European Patent Application EP-A-0 659 764 m the name of the Applicant incorporated herein by reference. The reduction reaction is generally carried out at a pH of between 1 and 10, preferably at a physiological pH of between 5 and 8, more preferably at a pH of from 5 to 6. The possibility of working at a physiological pH, with a good yield, is a further advantage of the method of the invention. The method of the invention will be further described by means of the following examples and appended drawings. In the drawings : - Figure 1) shows time-activity curves representing the variation of the percentage of [ l Re0 4 ] activity in the course of the reactions: (a) ['^ReO + SnCl, (0.2 mg) → [ ls ReO( DMSA) ] and (b) [ l Re0 4 ] + SnCl, (0.2 mg) + 7-cyclodextrm (10 mg) → [ π ReO(DMSA),] - Figure 2) shows time-activity curves representing the variation of the percentage of [ l8, Re0 4 ] " activity in the course of the reactions : (a) [ l)w Re0 4 ]- + SnCl, (1.0 mg) → [ i,, ReO( DMSA) ,] " and (b) [ lx *Re0 4 ]- + SnCl, (1.0 mg) + 7-cyclodextrin (10 mg) → [ l8 *Re0(DMSA),]- - Figure 3) shows time-activity curves representing the variation of the percentage of [ |,, Re0 4 ] " activity in the course of the reactions : (a) [ lxs Re0 4 ] " + SnCl, (0.2 mg) → [ lxx ReO(DMSA) ,] " and (b) [ lfW Re0 4 ]. " + SnCl_, (1.0 mg) + 7-cyclodextrin (10 mg) + oxalate (6 mg) → [ " x ReO( DMSA),] " Example 1 To a vial containing 2.5 mg of dimercaptosuccmic acid (DMSA below), 10.0 mg of 7-cyclodextrin and 92.0 mg of potassium oxalate were added 1.0 mg of SnCl,.2H,0 dissolved in 0.10 ml of an aqueous solution of acetic acid (20% v/v), which was followed by the addition of 0.4 ml of an aqueous solution of acetic acid (20% v/v) and 0.250 ml of saline. To the resulting solution were added 0.250 ml of a solution eluted from a [ l,,s Re ] [ Re0 4 ] " generator (activity in the range 50 to 500 MBq) (pH = 5.5) and the vial was kept at ambient temperature (or at 100°C) . The formation of the final complex [ ReO(DMSA) ,] " occurred almost instantaneously, with a radiochemical yield of more than 95%. In the present example and in the following the resulting products were characterised by HPLC and TLC . Example 2 The procedure given in Example 1 was carried out in exactly the same way with the addition, however, of 0.2 mg of SnCl,.2H_,0; the final complex formed almost instantaneously with a radiochemical yield of more than 95%. Example 3_ The procedure of Example 1 was carried out in exactly the same way with the use, however, of 0.02 mg of SnCl,.2HιO; the formation of the final product was complete after fifteen minutes with a radiochemical yield of more than 95%. Example 4 . To a vial containing 10.0 mg of 7-cyclodextrin and 92.0 mg of potassium oxalate were added 1.0 mg of SnCl,.2H,0 dissolved in 0.10 ml of an aqueous acetic acid solution (20% v/v), with the subsequent addition of 0.40 ml of aqueous acetic acid solution (20% v/v) and 0.250 ml of saline. Subsequently there were added 0.250 ml of a solution elured from a generator of [ l , Re ] [ Re0 ] " (activity in the range 50 to 500 MBq) (pH = 5.5) and the vial was kept at ambient temperature (or at 100°C) for fifteen minutes. Finally there were added 1.25 mg of DMSA and the resulting mixture was kept at ambient temperature (or at 100°C) . The formation of the final product [ 1,Sft Re0(DMSA) ,] " was complete almost instantaneously with a radiochemical yield of more than 95%. Example 5_ The procedure of Example 4 was repeated in an identical manner, with the addition, however, of 0.2 mg of SnCl, .2H,0. The formation of the final product was complete almost instantaneously with a radiochemical yield of more than 95%. Example 6 . The procedure of Example 4 was carried out in an identical manner with the addition, however, of 0.02 mg of SnCl,.2H,0. The formation of the final product was complete after one hour with a radiochemical yield of more than 90%. Examples 7-13 The procedures of examples 1 to 6 were repeated in an identical manner with the use, however, of the ligands 3,6- diaza-1 , 8-octandithiol and 3 , 7-diaza-l , 9-nonadithiol instead of the DMSA. The radiochemical yields were greater than 95% in all tests. Example 14 : Preparation of [ l,x Re0(L) Cl ] To a vial containing 3.0 mg of LH-, (LH , = 3- diphenylphosphinopropionylglycyl-L- (S-benzyl)cysteinyl methyl ester) dissolved in 0.10 ml of methanol, 10.0 mg of 7-cyclodextrin and 92.0 mg of potassium oxalate, there were added 1.0 mg of SnCl .2H0 dissolved in 0.20 ml of an aqueous acetic acid solution (20% v/v), with a subsequent addition of 0.30 ml of aqueous acetic acid (20% v/v). To the resulting mixture were added finally 0.500 ml of a solution eluted from a generator of [ l,x Re ] [ Re0 4 ] (activity in the range 50 to 500 MBq) (pH = 5.5) and the vial was kept at ambient temperature (or at 100°C) for one hour. The formation of the final product gave a radiochemical yield of more than 95%. Example 15 The procedure of Example 14 was repeated in exactly the same way with the addition, however, of 0.2 mg of SnCl,. 2H,0. The formation of the final product gave a radiochemical yield of more than 95%. Example 16 : Preparation of [ lxx Re(0) (DMSA) _,] ' To a vial containing 6.0 mg of tris (2- sulphonatophenyl )phosphine sodium salt (TPPTS [P(C ή H 4 S0~.),]Na-,) , 10.0 mg of 7-cyclodextrin, 92.0 mg of potassium oxalate, 0.50 ml of an aqueous acetic acid solution (20% v/v) and 0.250 ml of saline, there were added 0.250 ml of a solution eluted from a generator of [ 1,, Re ] [ Re0 4 ] (activity in the range 50 to 500 MBq) (pH = 5.0) and the vial was kept at ambient temperature (or at 100°C respectively) for thirty minutes. There were then added 1.25 mg of DMSA and the resulting mixture was maintained at 100°C for thirty minutes. The formation of the final product gave a radiochemical yield of more than 95%. Example 17: Preparation of [ l,s Re(0) (DMSA), ] 0.2 mg of SnCl, (dissolved in 0.5 mL of 20% aqueous glacial acetic acid), 10.0 mg of 7-cyclodextrm, 30.0 mg of sodium oxalate and 2.5 mg of H,DMSA were placed in a vial followed by 0.250 mL of [ l Re0 ] (50MBq-500 MBq). The vial was kept at room temperature for 15 mm. Yield>95%. H2DMSA Example 18: Preparation of [ lxx Re(0) (BAT) ] 0.2 mg of SnCl, (dissolved in 0.5 mL of 20% aqueous glacial acetic acid), 10.0 mg of 7-cyclodextrin, 30.0 mg of sodium oxalate and 2.0 mg of H,BAT were placed in a vial followed by 0.250 L of [ lxx Re0 4 ] " ( 50MBq-500 MBq). The vial was kept at room temperature for 15 min. Yield>95%. H3BAT Example 19: Preparation of [ lx Re(0) ( L) CI ] 0.2 mg of SnCl, (dissolved in 0.5 mL of 20% aqueous glacial acetic acid), 10.0 mg of 7-cyclodextrin, 30.0 mg of sodium oxalate and 3.0 mg of LH_, were placed in a vial followed by 0.250 mL of [ lxx Re0 4 ] " ( 50MBq-500 MBq). The vial was kept at room temperature for 30 min. Yield>95%. Example 20: Preparation of [ IX Re(0) (P,N,)C1 0.2 mg of SnCl_, (dissolved in 0.5 mL of 20% aqueous glacial acetic acid), 10.0 of 7-cyclodextrin 30.0 mg of sodium oxalate and 3.0 mg of PιN,H_, were placed in a vial followed by 0.250 mL of [ lxx Re0] " (50MBq-500 MBq). The vial was kept at room temperature for 15 min. Yield>95%. P2N2H2 Example 21: Preparation of [ |,, Re (N) ( DEDC) _,] 0.2 mg of SnCl, (dissolved in 0.5 mL of 20% aqueous glacial acetic acid), 10.0 of 7-cyclodextrin 30.0 mg of sodium oxalate and 1.0 mg of N-methyl, S-methyl dithiocarbazate (HNN(CH 1 )C(S)SCH 1 were placed in a vial followed by 0.250 mL of [ lxx Re0 4 ] ~ (50MBq-500 MBq). The vial was kept at room temperature for 15 min. Successively, 5.0 mg of diethylenetriaminopentaacetic acid (DTPA) and 10.0 mg of the sodium salt of diethyldithiocarbamate (DEDC or [Et,NCS 2 ]Na) were added, and the vial was heated at 100 for 5 min. Yield>95%. NaDEDC Other preparations have been carried out by adding the host molecule and the secondary reducing agent Red to a commercial kit formulation of a specific ligand before labelling with [ lxx Re0 4 ]. This procedure has been carried out with two commercial kit formulations for the preparation of m Tc _ MD p and w « 'τc-MAG3 radiopharmaceuticals. The detailed procedures are reported in the following examples. Example 22: Preparation of [ lxx Re(MDP)] 0.2 mg of SnCl,, dissolved in 0.5 mL of 20% aqueous acetic acid, 10.0 mg of 7-cyclodextrin 30.0 mg of sodium oxalate were added to a vial containing a commercial cold (i.e. non radioactive) kit formulation for the preparation of Wm Tc- MDP, followed by 0.250 mL of [ lxx Re0 4 ]- (50MBq-500 MBq). The vial was kept at room temperature for 15 min. Yield>95%. H H MDP Example 23: Preparation of [ lxx Re(0) (MAG3 ) ] 0.2 mg of SnCl,, dissolved in 0.5 mL of 20% aqueous acetic acid, 10.0 mg of 7-cyclodextrin and 5.0 mq of sodium oxalate were added to a vial containing a commercial cold kit formulation of 9m Tc-MAG3, followed by 0.250 mL of [ lxx Re0 4 ]- (50MBq-500 MBq). The vial was heated at 100°C for 15 min. Yield>95%. The experimental results show that the method of the invention can be successfully applied to the labelling of various ligands. The yield of formation of the final complexes were always over 90%, and the labelling procedures have been carried out under very mild conditions. Based on experimental findings, the method appears to possess a wide applicability. The role played by the host molecule appears to be that of displacing the equilibrium position of the reduction reaction towards the formation of the final product. This influence on the course of the reduction process can be envisaged by comparing the curves describing the disappearance of the activity of [ |,s Re0 4 ] " as a function of time when the reactions of formation of the complex [ 18X Re(0) (DMSA) ] " were conducted both in the absence of y- cyclodextrin and in the presence of 10 mg of this compound. Fig. 1 illustrates the comparison between the curves obtained using only 0.2 mg of SnCl, and when 10.0 mg of 7- cyclodextrin were added to the preparation. It is apparent from Figure 1 that, at the same reaction time, the process using SnCl_, in combination with 7-cyclodextrin is more displaced towards the formation of the product [ 188 Re0(DMSA) ,] " than that containing only SnCl,. More specifically, on approaching the equilibrium at longer reaction times (180 min.), the residual percentage of [ 1X8 Re0 4 ] " remaining is always less when 7-cyclodextrin was present in the reaction procedure in comparison with the situation where it was not utilized. This effect has been observed with all the ligands employed in this study ranging from 50% to 15% depending on nature of the specific ligand and reaction conditions. It was particularly evident when the formation of the complex [ lxx Re(DMSA)_,] " was studied using 1.0 mg of SnCl, in combination with 10 mg of 7-cyclodextrin . Figure 2 reports the comparison between the time-activity curve obtained when only 1.0 mg of SnCl, were employed and that where 10.0 mg of 7-cyclodextrin were additionally used. It is important to emphasize here that the effect of displacing equilibrium exhibited by 7-cyclodextrin is maximum at longer reaction times (that is to say on approaching the equilibrium of the reduction process), and is almost independent on the concentration of 7- cyclodextrin . These findings strongly support the description of the role of the host species forming supramolecular aggregates with some rhenium or technetium intermediate complexes formed during the course of the reduction process. In terms of the activated complex theory, therefore, the effect of the host molecule can be described as due to a lowering of the activation energy of the overall reduction process brought about by the supramolecular interaction. Accordingly the function of the host molecule may be defined as a catalyst or accelerator. The combination of Sn i+ , oxalate and 7-cyclodextrin appears to be the most efficient reduction procedure for [ lx Re0 4 ]. Figure 3 compares the time-activity curve for the reaction conducted using only 0.2 mg of SnCl, with that obtained by including in the same reaction vial 6.0 mg of potassium oxalate and 10.0 mg of 7-cyclodextrin . The invention also provides kits for the preparation of radiopharmaceutical products which include one or more ligands able to bind to the radioactive rhenium or technetium metal, a reducing agent as described above, a compound selected from the cyclic oligosaccharides, crown ethers or cryptands and pharmaceutically acceptable vehicles and auxiliary substances such as antioxidants , stabilisers and thickeners. The components of the radiopharmaceutical kit may be combined in freeze-dried form or may be kept separate to be combined at the moment of use. The radiopharmaceutical composition is formed by the addition of the radioactive agent obtained from the generator .

Claims: CLAIMS 1. A method for the reduction of oxygenated compounds of rhenium or technetium with a reducing agent, characterised in that the reduction reaction is carried out in the presence of a macromolecular compound selected from the group consisting of cyclic oligosaccharides, crown ethers and cryptands, wherein said macromolecular compound is effective to displace the equilibrium of the reduction reaction toward the formation of the reduced species of said oxygenated compound. 2. The method according to Claim 1 wherein the reduction is carried out in the presence of a ligand which can form a complex with the rhenium or the technetium in their reduced states . 3. The method according to Claim 1 or Claim 2, in which the oxygenated compound is the perrhenate ion or the pertechnetate ion . 4. A method according to any of claims 1 to 3 wherein the reduction reaction is carried out in the presence of a secondary reducing agent consisting of a polycarboxylic acid or metal salt thereof. 5. A method according to any one of Claims 1 to 4 , in which the reducing agent is selected from the ions Sn 2+ , Fe 2+ and Cu 1+ . 6. A method according to Claim 5, characterised in that the reducing ion is introduced into the reaction medium in the form of a halide, a phosphonate or a salt of a polycarboxylic acid. 7. A method according to Claim 6, in which the polycarboxylic acid salt is selected from the group consisting of tartrates, citrates, oxalates, gluconates and glucoheptonates . 8. A method according to any one of Claims 1 to 4 , in which the reducing agent is selected from the group consisting of phosphines, alkali metal thiosulphites , dithionites, alkali metal dithionites and alkali metal borohydride . 9. A method according to any one of Claims 4 to 8 , in which the ligand is selected from the group consisting of phosphines, arsines, thiols, thioethers, isonitriles, amines, cyclic amines, polyamines, dithiocarbamates , dithiocarboxylates , Schiff bases, diaminodithiols , bis ( amino ) thiols , oximes, sugars, borates, amino acids, polyamino acids, peptides, peptides modified with phosphine groups and ligands including combinations of these groups. 10. A method according to Claim 9, in which the ligand is selected from the group consisting of dimercaptosuccinic acid, 3 , 6-diaza-l , 8-octandithiol , 3 , 7-diaza-l , 9- nonandithiol and tris ( 2-sulphonatophenyl )phosphine sodium salt . 11. A method according to Claim 9, in which the reduction reaction is carried out in the presence of a first ligand able to promote the stabilisation of the reduced state of the metal to form a complex which can undergo substitution reactions with other ligands, and in the presence of a second ligand which can undergo said substitution reaction with the first ligand to form a stable complex of the second ligand. 12. A method according to Claim 11, characterised in that the first ligand is a polycarboxylate compound, particularly an oxalate or a citrate. 13. A method according to any one of Claims 2 to 12, characterised in that the cyclic oligosaccharide is selected from modified or unmodified a- , β- and γ- cyclodextrins . 14. A method according to any one of the preceding claims, characterised in that the reduction reaction is carried out at a pH of from 5 to 8. 15. The use of macromolecular compounds selected from cyclic oligosaccharides, crown ethers and cryptands to reduce the reaction time in a reaction for the reduction of the perrhenate ion or the pertechnetate ion in the presence of a reducing agent. 16. A kit for the preparation of a radiopharmaceuticals of rhenium or technetium, including a ligand which can form a complex with the rhenium or technetium, a reducing agent and a compound selected from the cyclic oligosaccarhides , crown ethers and cryptands in which the components are mixed together or separate.

Inventors: BOLZATI CRISTINA, BOSCHI ALESSANDRA, DUATTI ADRIANO, FRANCESCHINI RODOLFO, UCCELLI LICIA, BOLZATI, CRISTINA, BOSCHI, ALESSANDRA, DUATTI, ADRIANO, FRANCESCHINI, RODOLFO, UCCELLI, LICIA
Applicants: BOLZATI CRISTINA, BOSCHI ALESSANDRA, DUATTI ADRIANO, FRANCESCHINI RODOLFO, SORIN RADIOFARMACI S R L, UCCELLI LICIA, BOLZATI, CRISTINA, BOSCHI, ALESSANDRA, DUATTI, ADRIANO, FRANCESCHINI, RODOLFO, SORIN RADIOFARMACI S.R.L., UCCELLI, LICIA
Application year: 1997
Main classification: A61K51
IPC codes: A61K51